Redbiotec is using its proprietary technology platform, rePAX®, to generate Virus-Like-Particles (VLPs) and protein complexes for vaccine development purposes. Whereas we have established successful customer collaborations, we always seek the opportunity for new partnerships to bring forward our internal projects or launch new ones.
More specifically, we have in-house programs on the Cytomegalovirus, the Papilloma and Respiratory viruses. The underlying technology platform we have developed for this purpose, rePAX®, allows us to further build any other vaccine, mimicking whole virus surfaces in short time.
Selected customers/ collaboration partners
Further undisclosed big pharma und biotech partners.
Selected technology partners
Redbiotec offers the following partnering opportunities
- Non-exclusive licenses are available for Redbiotec’s technology platform rePAX® for the development of new vaccines against complex viruses
- Licensing opportunities of existing programs for vaccine development against CMV, HPV and Influenza
- Collaborations on ongoing programs that involve the production of VLPs for members of the Herpesvirus family
- Collaborations on projects upon customer’s demand based on Redbiotec’s know-how and proposals
Please contact us to discuss collaboration opportunities.